Bio/Pharma News

GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition

February 21, 2024

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

FDA Approves Amtagvi, First Cell Therapy for Skin Cancer

February 20, 2024

FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.

BioVaxys Acquires Full Portfolio of Former IMV

February 15, 2024

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

Novartis to Acquire MorphoSys for Roughly $2.9 Billion

February 08, 2024

Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.

Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition

February 01, 2024

With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.

FDA Grants Orphan Drug Designation to First-in-Class Treatment for Eosinophilic Esophagitis

January 31, 2024

The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.

IMU Biosciences Raises Millions in Series A Funding Round

January 30, 2024

IMU Biosciences has secured £11.5 million in its Series A financing round.

Sanofi to Aquire Inhibrx for $1.7 Billion

January 29, 2024

The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.

Takeda’s Subcutaneous Immunoglobulin Receives FDA Approval for Maintenance Therapy of Rare Neuromuscular Disorder

January 24, 2024

Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

January 16, 2024

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.